KIT and gastrointestinal stromal tumor: Unlike KIT-signaling inhibition, MAPK inhibition is not sustained in GIST cells exposed to imatinib, and a rebound of ERK activity occurs shortly thereafter, thus hindering GIST cell eradication ([23]; Figure 2F,H).